Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

This is a phase II single arm, open-label clinical trial determining diagnostic accuracy of Flotufolastat F18 PET in subjects with prostate adenocarcinoma. These are subjects who have not previously received treatment for prostate cancer.

NCT Number	NCT07568756
Lead Sponsor	University of California, Irvine Collaborators: Blue Earth Diagnostics
Conditions	Prostate Adenocarcinoma, Prostate Cancer
Enrollment	60 participants
Start Date	2026-05
Primary Completion	2028-05 (estimated)
Study Completion	2029-05 (estimated)
Updated on ClinicalTrials.gov	2026-05-06